Peptide Reference
Dulaglutide
Dulaglutide
A once-weekly GLP-1 receptor agonist (Trulicity) approved for type 2 diabetes with cardiovascular benefits. Convenient single-dose pen.
Status
approved
Category
weight loss
Typical cost
$800-1000/month (brand)
Mechanism
Activates GLP-1 receptors to improve glycemic control and reduce appetite. Weekly formulation provides sustained coverage. Cardiovascular benefits demonstrated in REWIND trial.
Potential benefits
- Convenient weekly dosing
- Good glycemic control
- Cardiovascular protection
- Moderate weight loss 5-8%
- Easy-to-use pen
Reported side effects
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Injection site reactions
Common dosing references
subcutaneous
0.75-4.5mg · Weekly
Ongoing
Research notes
REWIND trial - Dulaglutide cardiovascular outcomes
2019
Significant reduction in cardiovascular events in type 2 diabetes
Regulatory and sourcing notes
FDA-approved (Trulicity) for type 2 diabetes. Not specifically approved for weight, though weight loss occurs.
Prescription required. Good option for diabetes with cardiovascular concerns. Less weight loss than semaglutide.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides